LinkedIn Icon Twitter Icon
Dates TBC (March 2019) | Boston, MA

Day One
Tuesday, March 20 2018

Day Two
Wednesday, March 21 2018

Chair’s Opening Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

Pioneering Rational Combination Approaches

Keynote: Enhancing Patient Outcomes With Pembrolizumab In Combination Strategies

  • Roger Dansey SVP, Global Clinical Development Oncology, Merck


  • Investigating diverse combination strategies with pembrolizumab
  • Critical considerations for developing effective combination strategies – improving outcomes and maintaining tolerability
  • Understanding clinical combinations: biologic rationale and expecting the unexpected

Keynote: Addressing the Tidal Wave of Cancer Immunotherapy Combinations Through Innovative Trial Designs

  • Edward Cha Medical Director, Cancer Immunotherapy Franchise, Genentech


  • Highlighting the opportunity for novel clinical trial designs to address developmental challenges in the cancer immunotherapy space
  • Investigating the current state of cancer immunotherapy combination development across the industry
  • Understanding key clinical development challenges for cancer immunotherapy combination development
  • Developing a combination platform to increase the speed of identification of transformative signals
  • Examples of novel clinical trial designs to address combination development challenges

Predicting Marketed PD-1 Dosing and Optimal PD-1 x TIM-3 Dual Targeting Approaches in Immuno-Oncology

  • John Burke Co-Founder, President & CEO , Applied BioMath


Developing and interrogating a systems pharmacology model provides early quantitative decision making guidance for project teams.  In this presentation we will look at how interrogating a systems pharmacology model of the co-modulation inhibitory receptors PD-1 and TIM-3 in immuno-oncology helped to:

  • Assess risk by performing an in silico differentiation for a bispecific vs. FDC
  • Analyze why BMS and Merck anti-PD-1s therapeutic antibodies have similar dosing regimens when their affinities differ by two orders of magnitude
  • Provide predictions of the best-in-class profile for a PD-1 and TIM-3 dual antagonist biologic(s)

Speed Networking & Morning Refreshments

Identifying Translationally Relevant Biomarkers

11.00 Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology


  • Developing and clinically validating a fully human ex vivo platform technology (CANscript™)
  • Using patient material (tumor, autologous ligands and PBMC) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modalityagnostic way using phenotypic effects
  • Explore how CANscript was used to model the effect of checkpoint inhibition in HNSCC as a means of identifying predictors of clinical response and uncovering mechanisms of resistance

Mark Paris, Associate Director, Translational Applications, Mitra Biotech

11.30 From Bench to Clinic: Developing Biomarker Strategies for Immunotherapy Combinations

  • Using a deep understanding of target biology to narrow the list of candidate biomarkers that relate to the mechanism of action of a given drug
  • Challenges in interpreting biomarker data from combination studies

Jennifer Mataraza, Senior Investigator ll, Group Leader, Translational Immuno-Oncology, Novartis

12.00 Enabling Multidimensional Biomarker Discovery: Interrogating the Tumor, its Microenvironment, and Neoantigens with ACE ImmunoID

  • Introduce ACE ImmunoID as a universal platform for immuno-oncology and rational combination therapy development
  • Overcoming common NGS challenges from poor sample quality and quantity, to sequencing gaps, for more precise and complete genomic date
  • Facilitating comprehensive tumor immunogenomic characterization with integrated analytics for neoantigens, HLA, immunomodulators, adaptive and innate immunity, cytokines and chemokines, cytotoxicity, and mechanisms of tumor escape

Christelle Johnson, Senior Field Applications Scientist, Cancer Genomics & ImmunoOncology, Personalis


12.30 Lunch & Networking

‘Extreme Personalized Medicine’ – The Future of Immuno-Oncology?

13:30 Pharmacodynamic & Predictive Biomarkers in Clinical Development of JTX-2011, an ICOS Agonist

  • Identifying two important biomarkers for clinical development through preclinical efficacy studies
  • Using a pharmacodynamic biomarker in Phase 1 to identify the recommended Phase 2 dose
  • Selecting indications and enriching patient enrolment in Phase 2 using a potential predictive biomarker

Beth Trehu, CMO, Jounce

14.00 Beyond PD-L1: Understanding Novel Translational Biomarkers to Stratify Patients Effectively for Personalized Cancer Immunotherapy

  • Analyzing patient level biomarker stratification approaches to compare novel immunotherapy combinations more accurately
  • Combining new omics technologies to give a comprehensive picture of the tumor microenvironment to guide immunotherapy applications
  • Evaluating large data sets to discover gene signatures that will enhance the predictability of clinical outcomes

Jianda Yuan, Director, Translational Immuno-Oncology Research, Merck

14.30 Integrative Analyses of Microbiota, Environment, and Tumor Immunity for Personalizing Immunotherapy

  • Broadening the scope – understanding environmental and microbial factors that affect patient responses to immunotherapy
  • Analyzing human samples to investigate the influence of exposome (exposures) and microbiome on immune responses
  • Examining factors like microsatellite instability and neoantigen load that affect immunotherapy outcomes

Shuji Ogino, Professor, Dana-Farber Cancer Institute

Achieving Preclinical & Clinical Success Through Rational Combinations

11.00 Investigating Combination Strategies to Overcome Mechanisms of Resistance to Checkpoint Modulators

  • Assessing our understanding of mechanisms of resistance and how patients develop resistance to checkpoint inhibitors
  • Evaluating how rational combination approaches may overcome resistance
  • Exploring clinical combination trials to overcome resistance at various stages of the immune cycle

Osama Rahma, Assistant Professor of Medicine, Dana-Farber Cancer Institute

11.30 Investigating the Potential of TIM-3 & LAG-3 in the Context of Novel Combination Strategies

  • Understanding how substantial numbers of patients in all tumor types do not respond to anti-PD1/L1 therapy, and patients eventually progress on therapy, suggesting other mechanisms of immune escape persist across tumors
  • Learning about theLAG-3 and TIM-3 agents that are in development to address de novo refractory tumors and treatment emergent resistance
  • Providing an update on role of LAG-3 and TIM-3 in tumors and status of TSR-033 (anti-LAG3) and TSR-22 (anti-TIM3)

David Jenkins, Senior Director, Translational Strategy & Research, TESARO

12.00 Rational IO/IO & IO/ADC Combinations to Modulate the Immune System

  • Using the CD27 agonist antibody, Varlilumab, in combination with anti-PD1 antibody, Nivolumab, in advanced cancer patients
  • Rationale, preclinical and early clinical data combining the anti-gpNMB ADC Glembatumumab Vedotin with immunotherapy
  • Rationale and preclinical data for using a CD40 agonist antibody in IO combinations

Chris Turner, VP, Clinical Science, Celldex

12.30 Lunch & Networking

Driving Novel Combination Approaches Into The Clinic

13:30 Innate & Adaptive Integrin-Targeted Combination Immunotherapy

  • Developing an engineered integrin-binding peptide-Fc fusion that targets and recruits immune cell effector functions to tumors
  • Invoking innate and adaptive arms of the immune system through the co-administration of the peptide-Fc fusion and an immune modulator, such as a checkpoint blockade inhibitor, results in significant control of tumor growth

Jennifer Cochran, Associate Professor, Bioengineering, Stanford University

14.00 Investigating Combinations Involving Standard of Care Therapeutics & Immunomodulatory Agents

  • Gaining a mechanistic understanding of the role of radiotherapy in priming the immune system for checkpoint modulation
  • Case studies investigating the successful combination of these agents – what elements of the combination played a role in success?

Anna Tafuri, Global Early Clinical Lead, Bayer

14:30 NBTXR3: A New Modality Across the Board of Oncology

  • Developing in clinics first in class product for 7 patient subpopulations to improve local control, QoL and survival
  • Potential specific immune response compared to radiotherapy, impacting local control and systemic therapy
  • Evaluating the perspective of non-clinical and clinical IO combinations

Patrick Tricoli, CEO, Nanobiotix

Afternoon Refreshments & Poster Viewing

Turning Up the Heat on Cold Tumors by Engaging the Broader Tumor Microenvironment

Presentation details to be confirmed

  • James Keck Senior Director, In Vivo Pharmacology, The Jackson Laboratory

Evaluating the Role of Stromal Cells & TGFβ Signalling in the Resistance to Atezolizumab


  • Understanding the role of stromal cells in the tumor microenvironment and the effect of cross-talk with immune cells
  • Analyzing factors correlating with resistance to atezolizumab and reverse translating this information to provide meaningful preclinical insights
  • Building tools to study mesenchymal cells and their impact on immuno-oncology across tumor types

Chair’s Closing Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center